Compare Orchid Chemicals with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CADILA HEALTHCARE - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CADILA HEALTHCARE ORCHID PHARMA LTD/
CADILA HEALTHCARE
 
P/E (TTM) x -0.5 14.8 - View Chart
P/BV x 0.1 2.9 4.1% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ORCHID PHARMA LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CADILA HEALTHCARE
Mar-18
ORCHID PHARMA LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs194558 34.8%   
Low Rs35362 9.7%   
Sales per share (Unadj.) Rs276.5116.3 237.7%  
Earnings per share (Unadj.) Rs-79.217.9 -443.3%  
Cash flow per share (Unadj.) Rs-43.523.1 -187.8%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.985.4 63.1%  
Shares outstanding (eoy) m70.451,023.74 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.0 10.5%   
Avg P/E ratio x-1.425.7 -5.6%  
P/CF ratio (eoy) x-2.619.9 -13.3%  
Price / Book Value ratio x2.15.4 39.4%  
Dividend payout %019.6 0.0%   
Avg Mkt Cap Rs m8,067470,664 1.7%   
No. of employees `0002.811.8 23.7%   
Total wages/salary Rs m2,52718,545 13.6%   
Avg. sales/employee Rs Th6,956.110,072.7 69.1%   
Avg. wages/employee Rs Th902.51,569.1 57.5%   
Avg. net profit/employee Rs Th-1,993.01,547.7 -128.8%   
INCOME DATA
Net Sales Rs m19,477119,049 16.4%  
Other income Rs m4071,132 36.0%   
Total revenues Rs m19,884120,181 16.5%   
Gross profit Rs m1,10328,475 3.9%  
Depreciation Rs m2,5195,388 46.8%   
Interest Rs m5,227911 573.7%   
Profit before tax Rs m-6,23623,308 -26.8%   
Minority Interest Rs m20628 3.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1255,644 -2.2%   
Profit after tax Rs m-5,58018,292 -30.5%  
Gross profit margin %5.723.9 23.7%  
Effective tax rate %2.024.2 8.3%   
Net profit margin %-28.715.4 -186.5%  
BALANCE SHEET DATA
Current assets Rs m11,01482,005 13.4%   
Current liabilities Rs m32,06060,720 52.8%   
Net working cap to sales %-108.117.9 -604.4%  
Current ratio x0.31.4 25.4%  
Inventory Days Days9573 129.7%  
Debtors Days Days3498 34.1%  
Net fixed assets Rs m29,44083,703 35.2%   
Share capital Rs m7051,024 68.8%   
"Free" reserves Rs m2,04386,421 2.4%   
Net worth Rs m3,80087,445 4.3%   
Long term debt Rs m9,01825,551 35.3%   
Total assets Rs m46,510180,653 25.7%  
Interest coverage x-0.226.6 -0.7%   
Debt to equity ratio x2.40.3 812.2%  
Sales to assets ratio x0.40.7 63.5%   
Return on assets %-0.810.6 -7.2%  
Return on equity %-146.920.9 -702.0%  
Return on capital %-3.722.0 -17.0%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51342,683 17.6%   
Fx outflow Rs m5,64911,242 50.2%   
Net fx Rs m1,86531,441 5.9%   
CASH FLOW
From Operations Rs m1,6829,193 18.3%  
From Investments Rs m-9,860-9,737 101.3%  
From Financial Activity Rs m6,644515 1,290.1%  
Net Cashflow Rs m-1,535-29 5,293.1%  

Share Holding

Indian Promoters % 32.3 74.8 43.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.3 55.4%  
FIIs % 3.3 5.9 55.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 11.0 502.7%  
Shareholders   84,811 44,069 192.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS